Scinai Immunotherapeutics
SCNI
8 hedge funds and large institutions have $2.41M invested in Scinai Immunotherapeutics in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 0 closing their positions.
790% more capital invested
Capital invested by funds: $271K → $2.41M (+$2.14M)
14% more funds holding
Funds holding: 7 → 8 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.96K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
II
1
Ibex Investors
Denver,
Colorado
| $2.14M | – | – | – |
|
|
BHB
2
Bank Hapoalim BM
Tel Aviv,
Israel
| $148K | – | – | – |
|
3
HighTower Advisors
Chicago,
Illinois
| $96K | – | – | – |
|
|
LTFS
4
Ladenburg Thalmann Financial Services
Miami,
Florida
| $14K | – | – | – |
|
5
Royal Bank of Canada
Toronto,
Ontario, Canada
| $5K | – | – | – |
|
6
Wells Fargo
San Francisco,
California
| $5K | – | – | – |
|
7
Morgan Stanley
New York
| $4K | – | – | – |
|
|
8
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $2K | +$2.96K | +5 | New |
|
SCNI Hedge Fund Activity: Q3 2019 in Review
8 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q3 2019, worth a combined $2.41M — up 790% from $271K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SCNI positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Deutsche Bank, opening a new position worth an estimated $2.96K.
- 8 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q3 2019, up from 7 in Q2 2019.
- Funds reported $2.41M of Scinai Immunotherapeutics stock for Q3 2019, up 790% quarter-over-quarter.
- 1 fund opened new Scinai Immunotherapeutics positions in Q3 2019 and 0 closed out, a net change of +1 holder.
- The largest Scinai Immunotherapeutics buyer in Q3 2019 was Deutsche Bank, an estimated $2.96K added.
Based on aggregated 13F filings for Q3 2019.